Secretion of IL‐1β from imatinib‐resistant chronic myeloid leukemia cells contributes to BCR–ABL mutation‐independent imatinib resistance
Open Access
- 6 January 2016
- journal article
- research article
- Published by Wiley in FEBS Letters
- Vol. 590 (3) , 358-368
Abstract
Some cases of chronic myelogenous leukemia are resistant to tyrosine kinase inhibitors (TKIs) independently of mutation in BCR–ABL, but the detailed mechanism underlying this resistance has not yet been elucidated. In this study, we generated a TKI‐resistant CML cell line, K562R, that lacks a mutation in BCR–ABL. Interleukin‐1β (IL‐1β) was more highly expressed in K562R than in the parental cell line K562S, and higher levels of IL‐1β contributed to the imatinib resistance of K562R. In addition, IL‐1β secreted from K562R cells affected stromal cell production of CXCL11, which in turn promoted migration of K562R cells into the stroma. Thus, elevated IL‐1β production from TKI‐resistant K562R cells may contribute to TKI resistance by increasing cell viability and promoting cell migration.Keywords
Funding Information
- Korea Health Industry Development Institute
- Gwangju Institute of Science and Technology
This publication has 45 references indexed in Scilit:
- PTEN is a tumor suppressor in CML stem cells and BCR-ABL–induced leukemias in miceBlood, 2010
- BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistanceBlood, 2006
- The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET proteinCancer Cell, 2005
- Regulation of the c-Abl and Bcr–Abl tyrosine kinasesNature Reviews Molecular Cell Biology, 2004
- Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Philadelphia ChromosomePositive Leukemias: From Basic Mechanisms to Molecular TherapeuticsAnnals of Internal Medicine, 2003
- Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiationOncogene, 2000
- Mutator phenotype of BCR – ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase βOncogene, 1999
- TLS/FUS, a pro‐oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL‐mediated leukemogenesisThe EMBO Journal, 1998
- Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.Journal of Experimental Medicine, 1996